This Regulation lays down detailed procedural rules for joint scientific consultations carried out pursuant to Articles 16 to 21 of Regulation (EU) 2021/2282, as regards:
submission of requests from health technology developers for joint scientific consultation on medicinal products for human use (‘medicinal products’);
the selection and consultation of stakeholder organisations and patients, clinical experts and other relevant experts (‘individual experts’) in joint scientific consultation on medicinal products;
cooperation, in particular by exchange of information, with the European Medicines Agency on joint scientific consultations on medicinal products where a health technology developer requests the consultation to be carried out in parallel with the scientific advice on medicinal products by the European Medicines Agency pursuant to Article 57(1), point (n), of Regulation (EC) No 726/2004 (‘scientific advice’).